PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CluePoints Appoints Usama Dar as Chief Product and Technology Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has today announced Usama Dar as its new Chief Product and Technology Officer. Having led both product and R&D teams through significant expansion, Usama is ideally placed to help CluePoints in the next phase of its growth journey.

Usama has worked in leadership roles across some exciting organizations, including Westwing, Sciensus, Elsevier, The Guardian and Huawei. With a career spanning eCommerce, SaaS, and AI, he loves building and leading teams to create impactful products.

Andy Cooper, CEO at CluePoints, commented: “CluePoints has gone from being a very successful single-product company to a multi-product company undergoing a period of rapid growth, both in terms of people and our platform. Usama is the perfect fit to support us on our journey to provide the most comprehensive, and highest quality, Integrated Data Review platform for the Clinical Development industry.”

Usama Dar reiterated the opportunities for growth at CluePoints: “What attracted me to CluePoints was its mission to harness technology to improve and accelerate clinical trials, the people working within the organization and the difference I can make. CluePoints is at a sweet spot in its growth where it has a proven idea which is popular with customers. Now it needs to scale to more customers, more geographies and different parts of the clinical trial life cycle. I look forward to using my extensive engineering experience and product background to streamline product development, scale CluePoints’ offering and take it to the next level.”

Andy Cooper added: “Usama brings a strong vision of where our focus should be and what we need to bring from a technology perspective to ensure we do not just grow successfully but also provide best-in-class technology to underpin our products and ensure our customers are satisfied and can scale with us. Usama will be working closely with our existing team, including co-founder Francois Torche who will continue to lead the vision for our product portfolio as a strategic advisor.”

To learn more about CluePoints’ award-winning solutions, please visit www.cluepoints.com

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026